ESLA

Business Context and Reporting Period

Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. The company operates under a "reverse recapitalization" following its business combination with TradeUP Acquisition Corp. in September 2023. This 10-K covers the fiscal year ended June 30, 2024. The company relies heavily on Eureka Therapeutics, Inc. for research, development, and manufacturing services under a Services Agreement and a Statement of Work (SOW).

Key Financial Metrics

Note: The company has no revenue and no product candidates approved for sale. The decrease in R&D expenses in 2024 compared to 2023 was due to lower service fees from Eureka, partially offset by $3.5 million in milestone payments under a new SOW.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $3.8 million year-over-year, primarily driven by a significant reduction in R&D expenses ($4.1M vs $10.5M).
• Increased G&A Expenses: General and administrative expenses increased by $2.5 million, attributed to higher professional fees, stock-based compensation acceleration upon the business combination, and executive bonuses.
• Cash Position: Cash and cash equivalents increased by $1.7 million to $4.2 million, supported by net proceeds of approximately $20.1 million from the business combination and concurrent financing in the prior period, offset by significant operating cash outflows.
• Stock Repurchases: The company initiated a stock repurchase program in January 2024, repurchasing 321,794 shares for $354,440 during the fiscal year.

Guidance, Outlook, and Risks

Outlook and Milestones:

• EB103 Clinical Trial: The Phase I/II STARLIGHT-1 clinical trial for EB103 (CD19-Redirected ARTEMIS T-Cell Therapy) dosed its first patient in July 2024. As of September 2024, two patients have been dosed.
• EB104 Development: The company is compiling an IND filing for EB104, a dual-targeting (CD19/CD22) T-cell therapy.
• Solid Tumor Strategy: The company is researching a "mark and kill" strategy using EB103 in conjunction with Imugene's CF33-CD19t oncolytic virus for solid tumors.

Material Risks and Contingencies:

• Going Concern: The company has incurred recurring losses and negative cash flows. While management believes current cash and the White Lion equity line will fund operations for at least 12 months, substantial doubt remains regarding the ability to continue as a going concern without additional financing.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting related to a lack of qualified full-time accounting personnel. While remediation efforts began in fiscal 2024, management concluded disclosure controls were not effective as of June 30, 2024.
• Dependency on Eureka: The company relies on Eureka Therapeutics for R&D, manufacturing, and technical services. Termination of these agreements could halt operations.
• Warrants: Public warrants (ESLAW) have an exercise price of $11.50, significantly above the current stock price (~$1.00), making them unlikely to be exercised in the near term.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $4.2 million cash balance against the $33 million total fee commitment under the SOW with Eureka for the STARLIGHT-1 trial.
• Internal Control Remediation: Confirm the status of remediation for material weaknesses in financial reporting and the effectiveness of new controls.
• Clinical Progress: Monitor patient enrollment rates and safety data from the STARLIGHT-1 trial, as the first patient was only dosed in July 2024.
• Equity Line Status: Check if the company has utilized the $50 million equity line with White Lion Capital to raise additional capital.
• Related Party Payments: Track future milestone payments to Eureka, including the $50,000 payment made in July 2024 for the first patient dosing milestone.